.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,846,987

« Back to Dashboard

Claims for Patent: 5,846,987

Title: Retroviral protease inhibiting compounds
Abstract:A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
Inventor(s): Kempf; Dale J. (Libertyville, IL), Norbeck; Daniel W. (Crystal Lake, IL), Sham; Hing Leung (Gurnee, IL), Zhao; Chen (Gurnee, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:08/821,609
Patent Claims: 1. A combination pharmaceutical agent for the treatment of an HIV infection comprising (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl) methyl)-amino)carbonyl)valinyl)amino)-2-(N- ((5-thiazolyl) methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and a reverse transcriptase inhibitor.

2. The combination of claim 1 wherein the reverse transcriptase inhibitor is selected from the group consisting of dideoxycytidine (DDC), dideoxyinosine (DDI), BCH-189, AzdU, carbovir, DDA, D4C, D4T, DP-AZT, FLT (fluorothymidine), 5-halo-3'-thia-dideoxycytidine, PMEA and zidovudine (AZT).

3. The combination of claim 1 wherein the reverse transcriptase inhibitor is zidovudine.

4. The combination of claim 1 wherein the reverse transcriptase inhibitor is dideoxycytidine.

5. The combination of claim 1 wherein the reverse transcriptase inhibitor is dideoxyinosine.

6. The combination of claim 1 wherein the reverse transcriptase inhibitor is D4T.

7. The combination of claim 1 wherein the reverse transcriptase inhibitor is BCH-189.

8. The combination of claim 1 wherein (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl) methyl)-amino)carbonyl)valinyl) amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino) -1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the reverse transcriptase inhibitor are each formulated as separate compositions.

9. The combination of claim 8 wherein the formulation of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphe nyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the formulation of the reverse transcriptase inhibitor are to be administered at the same time.

10. The combination of claim 8 wherein the formulation of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl) methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl) -amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the formulation of the reverse transcriptase inhibitor are to be administered at different times.

11. A combination of pharmaceutical agents for the treatment of an HIV infection comprising (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphen yl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and a reverse transcriptase inhibitor.

12. The combination of claim 11 wherein the reverse transcriptase inhibitor is selected from the group consisting of dideoxycytidine (DDC), dideoxyinosine (DDI), BCH-189, AzdU, carbovir, DDA, D4C, D4T, DP-AZT, FLT (fluorothymidine), 5-halo-3'-thia-dideoxycytidine, PMEA and zidovudine (AZT).

13. The combination of claim 11 wherein the reverse transcriptase inhibitor is zidovudine.

14. The combination of claim 11 wherein the reverse transcriptase inhibitor is dideoxycytidine.

15. The combination of claim 11 wherein the reverse transcriptase inhibitor is dideoxyinosine.

16. The combination of claim 11 wherein the reverse transcriptase inhibitor is D4T.

17. The combination of claim 11 wherein the reverse transcriptase inhibitor is BCH-189.

18. The combination of claim 11 wherein (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl) methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)- amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the reverse transcriptase inhibitor are each formulated as separate compositions.

19. The combination of claim 18 wherein the formulation of (2S,3S,5S)-5-(N-(N-((N- Methyl-N-((2-isopropyl-4-thiazolyl) methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)- amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the formulation of the reverse transcriptase inhibitor are to be administered at the same time.

20. The combination of claim 18 wherein the formulation of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphe nyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the formulation of the reverse transcriptase inhibitor are to be administered at different times.

21. (2S,3S,5S)-5-(N- (N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)am ino)-2-(N-((5-thiazolyl) methoxycarbonyl)-amino)- 1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and a reverse transcriptase inhibitor for concomitant administration for the treatment of an HIV infection.

22. (2S,3S,5S)-5-(N-(N-((N-Methyl-N -((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-t hiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and zidovudine for concomitant administration for the treatment of an HIV infection.

23. (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-th iazolyl)methyl)-amino)carbonyl)valinyl) amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhe xane or a pharmaceutically acceptable salt thereof and dideoxycytidine for concomitant administration for the treatment of an HIV infection.

24. (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)meth yl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl) methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and dideoxyinosine for concomitant administration for the treatment of an HIV infection.

25. (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2 -isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiaz olyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and D4T for concomitant administration for the treatment of an HIV infection.

26. (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-th iazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycar bonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and BCH-189 for concomitant administration for the treatment of an HIV infection.

27. A combination pharmaceutical agent for administration to a human for the treatment of an HIV infection comprising:

a) a first pharmaceutical composition comprising (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphen yl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and

b) a second pharmaceutical composition comprising a reverse transcriptase inhibitor.

28. The combination of claim 27 wherein the reverse transcriptase inhibitor is selected from the group consisting of dideoxycytidine (DDC), dideoxyinosine (DDI), BCH-189, AzdU, carbovir, DDA, D4C, D4T, DP-AZT, FLT (fluorothymidine), 5-halo-3'-thia-dideoxycytidine, PMEA and zidovudine (AZT).

29. The combination of claim 27 wherein the reverse transcriptase inhibitor is zidovudine.

30. The combination of claim 27 wherein the reverse transcriptase inhibitor is dideoxycytidine.

31. The combination of claim 27 wherein the reverse transcriptase inhibitor is dideoxyinosine.

32. The combination of claim 27 wherein the reverse transcriptase inhibitor is D4T.

33. The combination of claim 27 wherein the reverse transcriptase inhibitor is BCH-189.

34. Use of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl) amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhe xane or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for concomitant administration to a human with a reverse transcriptase inhibitor for the treatment of an HIV infection.

35. The use of claim 34 wherein the reverse transcriptase inhibitor is selected from the group consisting of dideoxycytidine (DDC), dideoxyinosine (DDI), BCH-189, AzdU, carbovir, DDA, D4C, D4T, DP-AZT, FLT (fluorothymidine), 5-halo-3'-thia-dideoxycytidine, PMEA and zidovudine (AZT).

36. The use of claim 34 wherein the reverse transcriptase inhibitor is zidovudine.

37. The use of claim 34 wherein the reverse transcriptase inhibitor is dideoxycytidine.

38. The use of claim 34 wherein the reverse transcriptase inhibitor is dideoxyinosine.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc